User:Meyersm14/sandbox

David E. Edgren

Scientific Positions:

Principle Investigator XenoPort Public Company; Pharmaceuticals industry Currently holds this position

Research Fellow ALZA Corporation Public Company; JNJ; Pharmaceuticals industry 1975 – 2007 (32 years)

Number of Patents Currently Held:

Patent number: 5190763 Abstract A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy. http://www.google.com/patents?id=KB8gAAAAEBAJ&dq=david+edgren

Patent number: 5024842 Abstract A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug. http://www.google.com/patents?id=qBohAAAAEBAJ&dq=david+edgren

Patent number: 4946685 Abstract A bilaminate dosage form is disclosed comprising a first lamina and a second lamina with each lamina comprising a cellulose ether composition, and wherein a drug is present in at least one of the lamina. An optional coat is disclosed that surrounds the bilaminate form. http://www.google.com/patents?id=tgkhAAAAEBAJ&dq=david+edgren

Patent number: 4871548 Abstract A dosage form is disclosed comprising a low number average molecular weight hydroxypropylmethylcellulose, a high number average molecular weight hydroxypropylmethylcellulose, and a beneficial drug. http://www.google.com/patents?id=wWg5AAAAEBAJ&dq=david+edgren

Patent number: 4326525 Abstract An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in situ. http://www.google.com/patents?id=Whc9AAAAEBAJ&dq=david+edgren

Patent number: 5192550 Abstract A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy. http://www.google.com/patents?id=ea4iAAAAEBAJ&dq=david+edgren

Patent number: 5057321 Abstract A dosage form is disclosed comprising a drug and a maltodextrin polymer for administering to a patient a drug in need of therapy. http://www.google.com/patents?id=bvcmAAAAEBAJ&dq=david+edgren

Patent number: 4519801 Abstract An osmotic delivery system is disclosed for dispensing a useful agent. The system comprises a semipermeable wall surrounding a compartment housing the agent. The wall comprises a cellulose ether, an organic solvent soluble polymer, and optionally an aqueous soluble polymer. A passageway in the wall connects the interior of the system with the exterior for dispensing an agent from the system. http://www.google.com/patents?id=A0MsAAAAEBAJ&dq=david+edgren

Patent number: 5204116 Abstract A dosage form is disclosed comprising a first layer and a second layer. The first layer provides immediate therapy and comprises a drug stereoisomer and the second layer provides prolonged therapy and comprises a drug racemate. http://www.google.com/patents?id=xnAjAAAAEBAJ&dq=david+edgren

Patent number: 4522625 Abstract An osmotic dispenser is disclosed for releasing drug formulation in the gastrointestinal tract. The dispenser comprises a semipermeable-enteric wall surrounding a compartment housing drug formulation. A passageway in the wall communicates with the compartment for dispensing drug formulation. http://www.google.com/patents?id=O-YwAAAAEBAJ&dq=david+edgren

Patent number: 4587117 Abstract An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second environment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first environment and loses its integrity in the second environment. http://www.google.com/patents?id=8xcyAAAAEBAJ&dq=david+edgren

Patent number: 5128145 Abstract A dosage form is disclosed comprising a drug and a maltodextrin polymer for administering to a patient a drug in need of therapy. http://www.google.com/patents?id=sr8iAAAAEBAJ&dq=david+edgren

Patent number: 6120803 Abstract The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed. http://www.google.com/patents?id=ba0FAAAAEBAJ&dq=david+edgren

Patent number: 4503030 Abstract An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second environment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first environment and loses its integrity in the second environment. http://www.google.com/patents?id=giM6AAAAEBAJ&dq=david+edgren

Patent number: 4786503 Abstract A bilaminated dosage form is disclosed comprising at least 30 weight percent cellulose ether, a first lamina and a second lamina with each lamina comprising a different cellulose ether formulation, and a drug in at least one of the lamina. http://www.google.com/patents?id=IqkyAAAAEBAJ&dq=david+edgren

Patent number: 5221536 Abstract A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy. http://www.google.com/patents?id=Yf57AAAAEBAJ&dq=david+edgren http://www.google.com/patents?id=Yf57AAAAEBAJ&dq=david+edgren

Patent number: 4553973 Abstract An osmotic delivery system is disclosed for dispensing a useful agent. The system comprises a semipermeable wall surrounding a compartment housing the agent. The wall comprises a cellulose ether, an organic solvent soluble polymer, and optionally an aqueous soluble polymer. A passageway in the wall connects the interior of the system with the exterior for dispensing an agent from the system. http://www.google.com/patents?id=Gv04AAAAEBAJ&dq=david+edgren

Patent number: 5200194 Abstract An osmotic device (10) for delivering a beneficial drug, such as an anti-microbial drug, into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device comprises a thin semipermeable membrane wall (12) surrounding a compartment (13) housing a beneficial agent (14) that has at least some degree of solubility in aqueous biological fluids, e.g., saliva, and a fibrous support material (15) composed of hydrophilic water-insoluble fibers. A passageway (17) in the wall (12) connects the agent 14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the fibrous support material (15). The fibrous support material (15), once hydrated, provides a rigid support for the thin semipermeable wall (12) and prevents the device (10) from prematurely releasing the beneficial agent (14)...

http://www.google.com/patents?id=bdgdAAAAEBAJ&dq=david+edgren

Patent number: 4814181 Abstract A dosage form is disclosed comprising a wall that surrounds a compartment with an exit means in the wall. The compartment comprises a first or fast releasing lamina and a second or short releasing lamina that are delivered through the exit means over two different periods of time. http://www.google.com/patents?id=b7FxAAAAEBAJ&dq=david+edgren

Patent number: 5160743 Abstract A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug. http://www.google.com/patents?id=E4oiAAAAEBAJ&dq=david+edgren

Patent number: 5338550 Abstract A dosage form is disclosed comprising a first layer and a second layer. The first layer provides immediate therapy and comprises a drug stereoisomer and the second layer provides prolonged therapy and comprises a drug racemate. http://www.google.com/patents?id=SV8kAAAAEBAJ&dq=david+edgren

Patent number: 4931285 Abstract A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug. F http://www.google.com/patents?id=LnwcAAAAEBAJ&dq=david+edgren

Patent number: 4915953 Abstract A dosage form is disclosed comprising a wall that surrounds a compartment with an exit means in the wall. The compartment comprises a first or fast releasing lamina and a second or short releasing lamina that are delivered through the exit means over two different periods of time. http://www.google.com/patents?id=2sYnAAAAEBAJ&dq=david+edgren

Patent number: 4915954 Abstract A dosage form is disclosed comprising a wall that surrounds a compartment with an exit means in the wall. The compartment comprises a first or fast releasing lamina and a second or short releasing lamina that are delivered through the exit means over two different periods of time.

http://www.google.com/patents?id=28YnAAAAEBAJ&dq=david+edgren

Patent number: 6245357 Abstract A dosage form comprising a composition comprising a drug surrounded by an interior and an exterior wall with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy. http://www.google.com/patents?id=IzsIAAAAEBAJ&dq=david+edgren

Patent number: 4917895 Abstract A diffusional drug delivery device is described which can provide shelf life stability of the system components, elimination of the initial burst of drug and hence irritation, delayed onset of therapeutic effect and delivery of a therapeutic agent at an optimum rate. A metal layer and an activating means are inert when dry. Moisture activates the system whereby the activating means provides release of an eroding agent which erodes the metal layer through which the therapeutic agent diffuses and is subsequently delivered. http://www.google.com/patents?id=C9kaAAAAEBAJ&dq=david+edgren

Patent number: 4484921 Abstract An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in situ. http://www.google.com/patents?id=NhkwAAAAEBAJ&dq=david+edgren

Patent number: 5534263 Abstract The present invention is directed to an active agent dosage form which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface two or more insoluble bands. The invention is also directed to the method for making the active agent dosage form. http://www.google.com/patents?id=qT0lAAAAEBAJ&dq=david+edgren

Patent number: 4439195 Abstract An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in situ. http://www.google.com/patents?id=C945AAAAEBAJ&dq=david+edgren

Patent number: 6365183 Abstract The present invention is directed to an active agent dosage form and methods of its fabrication which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface one or more insoluble bands located in complementary grooves. The invention is also directed to articles of manufacture, methods and systems for fabricating the active agent dosage form. http://www.google.com/patents?id=zeIKAAAAEBAJ&dq=david+edgren

Patent number: 6342249 Abstract Controlled release of liquid, active agent formulations is provided by dispersing porous particles containing the liquid active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents. http://www.google.com/patents?id=9l0KAAAAEBAJ&dq=david+edgren

Patent number: 6210712 Abstract A dosage form comprising a composition comprising a drug surrounded by a first coat and a second coat with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy.

http://www.google.com/patents?id=JcMFAAAAEBAJ&dq=david+edgren

Patent number: 6514530 Abstract A dosage form is disclosed comprising means for delivering essentially a total dose of drug http://www.google.com/patents?id=Tq8NAAAAEBAJ&dq=david+edgren

Patent number: 6635281 Abstract The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid environment of use. The liquid, active agent formulation is sorbed into porous particles that are dispersed in a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix may be surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed. http://www.google.com/patents?id=VW8NAAAAEBAJ&dq=david+edgren

Patent number: 7060734 Abstract A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

http://www.google.com/patents?id=CLZ3AAAAEBAJ&dq=david+edgren

Patent number: 6797283 Abstract | Drawing | Description | Claims Abstract The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, formed of polymer matrices that swell upon contact with the fluids of the stomach. At least one layer of the multilayered dosage form includes an active agent. A portion of the polymer matrices are surrounded by a band of insoluble material that prevents the covered portion of the polymer matrices from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed. http://www.google.com/patents?id=FjMRAAAAEBAJ&dq=david+edgren

Patent number: 6387403 Abstract Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form. http://www.google.com/patents?id=8okKAAAAEBAJ&dq=david+edgren

Patent number: 7087243 Abstract A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time. http://www.google.com/patents?id=I1t6AAAAEBAJ&dq=david+edgren

Patent number: 6548083 Abstract The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix is surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed. http://www.google.com/patents?id=s7UNAAAAEBAJ&dq=david+edgren

Patent number: 6630165 Abstract Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form. http://www.google.com/patents?id=uDgNAAAAEBAJ&dq=david+edgren

Patent number: 6596314 Abstract Controlled release of liquid, active agent formulations is provided by dispersing porous particles containing the liquid active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents. http://www.google.com/patents?id=gJcNAAAAEBAJ&dq=david+edgren

Patent number: 5718700 Abstract A dosage form is disclosed comprising a wall that surrounds a bilayer core with exit passageway for communicating with the bilayer core in the wall http://www.google.com/patents?id=ohopAAAAEBAJ&dq=david+edgren

Patent number: 6440457 Abstract The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose. http://www.google.com/patents?id=b30KAAAAEBAJ&dq=david+edgren

Patent number: 5667804 Abstract The present invention is directed to an active agent dosage form which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface two or more insoluble bands. The invention is also directed to the method for making the active agent dosage form. http://www.google.com/patents?id=wHQoAAAAEBAJ&dq=david+edgren

Patent number: 5006346 Abstract A dosage form is disclosed comprising a coat that surrounds a drug. The coat comprises a subcoat and an overcoat thermally annealed to provide a single unit coat around the drug. http://www.google.com/patents?id=QSEoAAAAEBAJ&dq=david+edgren

Patent number: 6217905 Abstract A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy. http://www.google.com/patents?id=o_sFAAAAEBAJ&dq=david+edgren

Patent number: 6020000 Abstract The present invention is directed to an active agent dosage form that is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has an insoluble material circumscribing a portion of the surface of the matrix. The invention is also directed to a method of making the active agent dosage form. http://www.google.com/patents?id=sSUEAAAAEBAJ&dq=david+edgren

Patent List

Principle Investigator XenoPort (Public Company, Pharmaceuticals Industry) Currently holds this position

Research Fellow ALZA Corporation (Public Company; 1001-5000 employees; JNJ; Pharmaceuticals industry) 1975 — 2007 (32 years) Research Fellow Johnson & Johnson (Pharmaceuticals industry) 1975-2007 (32 years)

http://www.linkedin.com/pub/5/655/302

Patent #: 2041579 Abstract: Abstract of CA2041579 ARC 1741 A dosage form (10) is disclosed comprising an anti-Parkinson's disease drug (18) for administering to a patient in need of antiParkinson's disease therapy. Souce: http://www.wikipatents.com/ca/2041579.html

Application #: USPTO Application #: 20070225632 Abstract: Title: Hydratable polymeric ester matrix for drug electrotransport… Abstract: A transdermal electrotransport drug delivery system to an individual. The system has a liquid imbibing polymer with carboxyl groups available for noncovalently associating with a cationic drug. The liquid imbibing polymer is applicable for imbibing liquid before the device is deployed on a patient for electrotransport drug delivery Souce: http://www.freshpatents.com/Hydratable-polymeric-ester-matrix-for-drug-electrotransport-dt20070927ptan20070225632.php

Patent #: 4326525 Abstract: Osmotic device that improves delivery properties of agent in situ An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in situ. Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4439195 Abstract: Theophylline therapy An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in situ. Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4484921 Abstract: Theophylline therapy utilizing osmotic delivery An osmotic device is disclosed that provides a means for improving the delivery properties of a beneficial agent in Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #:  4503030 Abstract: An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second environment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first environment and loses its integrity in the second environment. Souce http://patentuniverse.com/US4503030.html

Patent #: 4519801 Abstract: Osmotic device with wall comprising cellulose ether and permeability enhancer An osmotic delivery system is disclosed for dispensing a useful agent. The system comprises a semipermeable wall surrounding a compartment housing the agent. The wall comprises a cellulose ether, an organic solvent soluble polymer, and optionally an aqueous soluble Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4522625 Abstract: Drug dispenser comprising wall formed of semipermeable member and enteric member An osmotic dispenser is disclosed for releasing drug formulation in the gastrointestinal tract. The dispenser comprises a semipermeable-enteric wall surrounding a compartment housing drug formulation. A passageway in the wall communicates with the compartment for dispensing drug form Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4553973 Abstract: Process for preparing osmotic device An osmotic delivery system is disclosed for dispensing a useful agent. The system comprises a semipermeable wall surrounding a compartment housing the agent. The wall comprises a cellulose ether, an organic solvent soluble polymer, and optionally an aqueous soluble polymer. A passageway Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4587117 Abstract: Medical device for delivering drug to pH environments greater than 3.5 An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second environment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first environment and loses its integrity in Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 4917895 Abstract: Transdermal drug delivery device A diffusional drug delivery device is described which can provide shelf life stability of the system components, elimination of the initial burst of drug and hence irritation, delayed onset of therapeutic effect and delivery of a therapeutic agent at an optimum rate. A metal layer and an Souce: http://www.patentgenius.com/inventor/EdgrenDavid.html

Patent #: 5667804 Abstract: Banded prolonged release active agent dosage form The present invention is directed to an active agent dosage form which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface two or more insoluble bands. The invention is also Souce: pat genius

Patent #:  5718700 Abstract: Exit means in dosage form.. A dosage form is disclosed comprising a wall that surrounds a bilayer core with exit passageway for communicating with the bilayer core in the wall. Souce: pat genius

Patent # 6020000 Abstract: Banded prolonged release active agent dosage form The present invention is directed to an active agent dosage form that is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has an insoluble material circumscribing a portion of the surface of the Souce: pat genius

Patent # 6217905 Abstract A dosage form is disclosed comprising an anti-Parkinson's disease drug for administering to a patient in need of anti-Parkinson's disease therapy Souce: pat genius

Patent #: 6245357 Abstract: A dosage form comprising a composition comprising a drug surrounded by an interior and an exterior wall with an exit for administering the drug to a patient; and a method of using the dosage form are disclosed for an indicated therapy. Souce: http://www.boliven.com/patent/US6245357

Patent # 6440457 Abstract The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose. Souce http://www.patentgenius.com/inventedby/EdgrenDavidEmilElGranadaCA.html